WO1995018864A1 - Method of producing derivatives of lactosamine - Google Patents
Method of producing derivatives of lactosamine Download PDFInfo
- Publication number
- WO1995018864A1 WO1995018864A1 PCT/SE1995/000010 SE9500010W WO9518864A1 WO 1995018864 A1 WO1995018864 A1 WO 1995018864A1 SE 9500010 W SE9500010 W SE 9500010W WO 9518864 A1 WO9518864 A1 WO 9518864A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- gal
- lactosamine
- compound
- derivative
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 57
- PNIWLNAGKUGXDO-LNCRCTFVSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r)-5-amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical class O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 PNIWLNAGKUGXDO-LNCRCTFVSA-N 0.000 title claims abstract description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- 239000000126 substance Substances 0.000 claims abstract description 21
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims abstract description 17
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims abstract description 17
- 241000222025 Hamamotoa singularis Species 0.000 claims abstract description 16
- 125000000962 organic group Chemical group 0.000 claims abstract description 16
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 11
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims abstract description 9
- 229960002442 glucosamine Drugs 0.000 claims abstract description 9
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims abstract description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 3
- 241000605059 Bacteroidetes Species 0.000 claims abstract 6
- 150000007824 aliphatic compounds Chemical class 0.000 claims abstract 2
- 150000001491 aromatic compounds Chemical class 0.000 claims abstract 2
- 102000004190 Enzymes Human genes 0.000 claims description 48
- 108090000790 Enzymes Proteins 0.000 claims description 48
- -1 ethyloxy Chemical group 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000005544 phthalimido group Chemical group 0.000 claims description 8
- 125000001931 aliphatic group Chemical group 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001905 inorganic group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 3
- 102000004195 Isomerases Human genes 0.000 claims description 3
- 108090000769 Isomerases Proteins 0.000 claims description 3
- 102000004316 Oxidoreductases Human genes 0.000 claims description 3
- 108090000854 Oxidoreductases Proteins 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 125000004001 thioalkyl group Chemical group 0.000 claims description 3
- 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 125000005336 allyloxy group Chemical group 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 230000009920 chelation Effects 0.000 claims description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000003586 protic polar solvent Substances 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
- 239000004593 Epoxy Substances 0.000 claims 1
- 125000003047 N-acetyl group Chemical group 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 108700040099 Xylose isomerases Proteins 0.000 claims 1
- 230000000397 acetylating effect Effects 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 68
- 239000000047 product Substances 0.000 description 60
- 239000000370 acceptor Substances 0.000 description 38
- 230000015572 biosynthetic process Effects 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 28
- 239000000348 glycosyl donor Substances 0.000 description 27
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 26
- 239000008101 lactose Substances 0.000 description 26
- 239000000758 substrate Substances 0.000 description 24
- 229930182470 glycoside Natural products 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 210000005253 yeast cell Anatomy 0.000 description 14
- 238000005481 NMR spectroscopy Methods 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000000386 donor Substances 0.000 description 13
- 238000000855 fermentation Methods 0.000 description 11
- 230000004151 fermentation Effects 0.000 description 11
- 229920001542 oligosaccharide Polymers 0.000 description 11
- 150000002482 oligosaccharides Chemical class 0.000 description 11
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 9
- PNIWLNAGKUGXDO-UHFFFAOYSA-N Lactosamine Natural products OC1C(N)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 PNIWLNAGKUGXDO-UHFFFAOYSA-N 0.000 description 9
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 9
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- DOVBXGDYENZJBJ-ONMPCKGSSA-N lactosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DOVBXGDYENZJBJ-ONMPCKGSSA-N 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 235000017281 sodium acetate Nutrition 0.000 description 9
- 239000001632 sodium acetate Substances 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 108700023372 Glycosyltransferases Proteins 0.000 description 7
- 102000051366 Glycosyltransferases Human genes 0.000 description 7
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 239000006184 cosolvent Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 229920005654 Sephadex Polymers 0.000 description 6
- 239000012507 Sephadex™ Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 150000002016 disaccharides Chemical class 0.000 description 6
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000005918 transglycosylation reaction Methods 0.000 description 6
- 238000005100 correlation spectroscopy Methods 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 5
- 150000002338 glycosides Chemical group 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000011343 solid material Substances 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical group OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000001311 chemical methods and process Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 3
- 102000005262 Sulfatase Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000011143 downstream manufacturing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 150000002301 glucosamine derivatives Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 108060007951 sulfatase Proteins 0.000 description 3
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000002464 Galactosidases Human genes 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 102000003838 Sialyltransferases Human genes 0.000 description 2
- 108090000141 Sialyltransferases Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- LQEBEXMHBLQMDB-UHFFFAOYSA-N [[5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] (3,4,5-trihydroxy-6-methyloxan-2-yl) hydrogen phosphate Chemical compound OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 229940060155 neuac Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 125000005630 sialyl group Chemical group 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 108010083651 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase Proteins 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241000235172 Bullera Species 0.000 description 1
- 0 C*C(C(*)C1O)OC(CO)C1O[C@](C(C(O)O)O)*=*C Chemical compound C*C(C(*)C1O)OC(CO)C1O[C@](C(C(O)O)O)*=*C 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 229930182475 S-glycoside Natural products 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- USAZACJQJDHAJH-KDEXOMDGSA-N [[(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-6-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](C=2NC(=O)NC(=O)C=2)O1 USAZACJQJDHAJH-KDEXOMDGSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SQDFRWJUKVCUOT-JGMUFZQJSA-N beta-D-Galp3S-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O SQDFRWJUKVCUOT-JGMUFZQJSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- YVECGMZCTULTIS-PBXRRBTRSA-N glucal Chemical compound OC[C@H]1OC=C[C@@H](O)[C@@H]1O YVECGMZCTULTIS-PBXRRBTRSA-N 0.000 description 1
- 125000002566 glucosaminyl group Chemical group 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- FGYNENQLWILFLQ-UHFFFAOYSA-N n-[3,4,5-trihydroxy-1-oxo-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)NC(C=O)C(O)C(O)C(O)COC1OC(CO)C(O)C(O)C1O FGYNENQLWILFLQ-UHFFFAOYSA-N 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 125000001209 o-nitrophenyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])[N+]([O-])=O 0.000 description 1
- 150000002894 organic compounds Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000006098 transglycosylation Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 150000008495 β-glucosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
Definitions
- the present invention describes a new method for the production of certain carbohydrate containing compounds related to glycoconjugates,- namely, lactosamine derivatives and substances derived therefrom.
- the present invention relates to products produced by the above method as well as uses of the resulting products.
- Glycoconjugates contain saccharide chains with from one up to twenty monosaccharide units and in which certain sequences have been shown to have biological activity, for example in the binding of different cells, pathogens, toxins, as well as antibodies or other proteins to cell surfaces, in cancer metastasis, in inflammatory processes, for instance selectin- carbohydrate interactions in the binding of white blood cells to the blood vessel wall, as a modifier of the biological activity and stability of glycoproteins, as immunogenic substances, which have potential in the vaccination against different diseases (See for instance Annual Review of Biochemistry, vol. 58 (1989) , pages 309-350, and Current Opinion in Structural Biology, for example review articles in vol. 3 (1993) and references therein) .
- Structures containing the sequence Gal / 3l-4GlcNAc, called N-acetyl-lactosamine below, are especially of importance and are found for instance in glycoconjugate oligosaccharides of the lactosamine type.
- the structure is found in blood group structures, for instance Lewis-x (e.g. Gal3l-4 (Fuc ⁇ l-3) GlcNAc) , sialyiated Lewis-x and 3'-sulfated Lewis-x, and is of importance in e.g. ⁇ electin-carbchydrate interactions (as reviewed by J.B. Lowe, in Molecular Glycobiology, pages 163-205, Fukuda and
- Enzymatic methods used before the present method were mainly 5 based on the use of galactosyltransferase (EC 2.4) , a cofactor dependent enzyme which requires UDP-galactose as a glycosyl donor (e.g. Wong et al. , J. Org. Chem. (1982) , pages 5416-5418) .
- This type of enzyme also has disadvantages as high acceptor selectivity and exhibits low efficiency with unnatural
- acceptors for instance derivatives of glucosamine (e.g. as reviewed by Khan and Hindsgaul in Molecular Glycobiology, pages 206-229, Fukuda and Hindsgaul, Eds., IRL Press at Oxford University Press, Oxford, 1994) .
- derivatives of glucosamine e.g. as reviewed by Khan and Hindsgaul in Molecular Glycobiology, pages 206-229, Fukuda and Hindsgaul, Eds., IRL Press at Oxford University Press, Oxford, 1994.
- K.G.I. Nilsson, Trends in Biotechnology, i-i 1988, p. 256-264 the nomenclature used in that review article and in this application follow the same IUPAC-rules
- Glycosidases have been used to produce N-acetyl-lactosamine and N-acetyl-allolactosamine from galactosides and N-acetyl- glucosamine (Sakai et al. , J. Carbohyd. Chem, 11: 553-565,
- the present invention describes a method which with unexpectedly high specificity gives the j ⁇ l-4 linkage in the synthesis of different lactosamine derivatives, using abundant donor substances such as lactose and other low cost galactosyl 35 donor substances.
- the method is carried out by using the yeast Bul lera singularis as a catalyst (classified as Bullera singularis according to Yeasts, second edition by Barnett et al . , Cambridge University Press, 1990) .
- the process of the invention is carried out by using enzymes (which belongs to the group of glycosidases, EC Group 3.2) , preferably in a crude, partially isolated or isolated form, especially jS-galactosidase from Bullera singularis but also other /3-galactosidase e.g. recombinant, of the same structure or of a similar structure (e.g., containing similar active site structure) as the one from Bullera singularis .
- enzymes which belongs to the group of glycosidases, EC Group 3.2
- jS-galactosidase from Bullera singularis but also other /3-galactosidase e.g. recombinant, of the same structure or of a similar structure (e.g., containing similar active site structure) as the one from Bullera singularis .
- the process for producing lactosamine derivatives can be carried out as an equilibrium (reversed hydrolysis) reaction or preferably as a kinetic (transglycosylation) reaction.
- an equilibrium reaction reversed hydrolysis
- a kinetic reaction transglycosylation
- the glycosyl donor is a glycoside, e.g. of D-galactose (Gal) modified in the C-1 position (anomeric position) but it can also be an oligosaccharide, such as lactose (GalSl-4Glc or aglycoside thereof, e.g. :
- R can be a glycosidically linked organic group, for example sugar (e.g. C-.H-.-O., or C n H 2r ._ 2 O n - 1 such as glucose) , lower alkyl group (e.g. -Me, -Et) or an aromatic group (e.g. phenyl (-Ph) , umberriferyl or m- , o- , or p-nitrophenyl group) , preferably R is Glc (glucose) or nitrophenyl .
- Other glyco ⁇ ides e.g. F- , N- or S-glycosides may be selected.
- glycosidases allow some modification of the glycon part (i.e., the galactosyl part in ' the present invention) of the glycosyl donor. Therefore, in addition to Gal/30R, donors where the galactosyl part have been partially modified in a way still allowing the transglycosylation reaction to occur, resulting in the ⁇ l -A linkage between the glycon part of the glycosyl donor and the glucosamine derivative, can be selected by the person skilled in the art for use with the method according to the present invention. Examples of such modifications of the glycon are modifications where at least one of the hydroxyl groups have inverted configuration (e.g.
- inversion in position 4 means that Gal is substituted for by Glc, that is Glc ⁇ OR, i.e. a ⁇ - glucoside, is used as donor) , or where one of the hydroxyl groups of Gal has been modified or substituted for by an inorganic (e.g. -F, -H) or an organic group, e.g. a lower alkyl (e.g. methyl), allyl or an acetyl group.
- an inorganic e.g. -F, -H
- organic group e.g. a lower alkyl (e.g. methyl), allyl or an acetyl group.
- Products of the type R' -Gal / 31- 4GlcNR' ' -R' ' ' may thus be prepared where R' -Gal relates to a modified glycon of the glycosyl donor.
- the glycosyl donor in the scheme shown below, R' -Gal-R is a /?-glycoside: R'-Gal-R + GlcNR''-R"' R' -Galj3l-4GlcNR" -R" ' + RH
- the transglycosylation reaction is a /?-glycoside: R'-Gal-R + GlcNR''-R"' R' -Galj3l-4GlcNR" -R" ' + RH
- the reaction rate is higher than in the equilibrium reaction since the glycoside or disaccharide is more reactive than the non-activated sugar D-galactose used as donor in the equilibrium reaction.
- An enzyme of less purity, even a non-purified enzyme, can be used in the reaction since the enzymes are substrate/linkage specific and contaminating enzymes (e.g., a- galactosidase) will not react with Gal ⁇ OR to give a /-.-linked product.
- intact cells e.g. yeast
- partially purified enzyme or enzyme of higher purity can be used as well as partially purified enzyme or enzyme of higher purity.
- Hydrolysis of Gal/30R will also occur to a certain extent depending on the reaction conditions.
- Lower or higher temperatures e.g., room temperature or higher, e.g. 25°-65°C
- organic (co) solvents acetone, acetonitrile, tetrahydrofurane
- the pH typically is selected from the range 4 to 8
- the substrate concentrations are typically 30 mM to several M concentration (e.g. 7 M) depending on the solubility of the substrates, stability of enzyme in the reaction mixture, and the particular goal of the reaction and the type of substrates.
- the reaction will go through a maximum of product formation and has to be followed (e.g., preferably by HPLC) and terminated after an appropriate time by e.g. heat treatment at e.g. 80°-100°C for e.g. three minutes.
- donor consumption is tracked and the reaction terminated after a suitable time, which depends on the conditions, and often at .> 40% consumption of the donor.
- the reaction can be carried out for a few minutes to several hours depending on the growth of yeast cells (if fermentation conditions are used) , the amount of enzyme, temperature, pH, concentration of substrates, and other factors.
- the reaction can be monitored by means of TLC, HPLC or by spectrophoto etric measurement of liberated aglycon (e.g. nitrophenol, 400 n ) . Charring of TLC plates with sulfuric acid may be used for detection of sugars.
- the reaction is terminated by denaturation of the enzyme by for example heat treatment. Heating to 85°C or above for 3-5 min (eventually followed by addition of ethanol to a concentration of about 80%) is usually sufficient. If immobilized enzyme is used, the reaction may be terminated by centrifugation or filtration.
- R' ' -HAc group in the 2 position, i.e. in the N-pc ⁇ ition of 2-glucosamine; the 2-pcsition in glucosamine contain a -NHAc
- R' ' ' represents an aglycon other than the anomeric hydroxyl group (i.e. R' ' ' is not CH) . If R" is not a -HAc group then R' ' ' can be OH but can also represent a modification of the anomeric hydroxyl group as in the case where R' ' is -HAc.
- the method according to the invention can be used to produce Gal/?l-4GlcNR' ' -R' ' ' in high purity (no other linkages observed by 400 MHZ NMR) , a product which after isolation can be used for biological/therapeutical purposes or for further synthesis according to the invention.
- the method can also be used to produce Gal/?l-4Gal/3l-4GlcNR' ' -R' ' ' .
- Gal ⁇ l - 4Gal / 8l-4GlcNR' ' -R' ' ' as shown by the following equation:
- GlcNR' ' -R' ' ' (the derivative of glucosamine which is used as acceptor) , is of the general structure shown in the example below:
- NR' ' may be selected from compounds containing an inorganic group (e.g. N 3 , NHS0 3 H) and/or an organic group bound to the 2 position of glucosamine, such as (a)
- N-phthalimido (b) an organic carbonyl group NH-C(0)-R where R is a hydrogen or a compound containing an organic group, e.g. aliphatics such as alkyl (e.g. methyl, ethyl, propyl) , alkoxy (e.g.
- NHR where R is a compound containing an aliphatic and/or aromatic group as described above, for example lower alkyl, preferred examples include NH(CH 2 ) n CH, (n is an integer equal to or greater than 1) ; or (d) NRR' where R and R' are independently selected from compounds containing an aliphatic and/or aromatic group as described above; preferably NR' ' is azido, 2-N-acetyl-, cr 2-N-phthalimido; and where R'
- fluoro or is selected from an O- , C- , N- or S-glycosidically bound compound containing an aliphatic and/or aromatic group, for example lower alkoxy (e.g. methyloxy (-OMe) , ethyloxy (-OEt)), lower thioalkyl (e.g. 3-linked thioethyl (-SEt)) , thioaromatic (e.g.
- lower alkoxy e.g. methyloxy (-OMe) , ethyloxy (-OEt)
- lower thioalkyl e.g. 3-linked thioethyl (-SEt)
- thioaromatic e.g.
- R' ' ' can be -OH if NR' ' is not NHAc but R' ' ' is not -OH if NR' ' is NHAc.
- the Gal/3l-4GlcN (lactosamine) containing product obtained with GalJOR as donor in the method according to the present invention is of the general structure shown in the example below:
- Such conjugates where lactosamine, or higher oligosaccharides containing the lactosamine structure, is N- or O-glycosidically bound to amino acids or peptide sequences, via che glucosamine residue in lactosamine and derivatives thereof as described above, are of interest to produce synthetically for fundamental studies and for synthesis of biologically/medically active fragments of glycoproteins, for instance to be used as vaccine or therapeutics. It is also important to be able to synthesize oligosaccharide analogues/derivatives of the structures above and according to the present invention to modify or improve the biological activity of the conjugate.
- the synthetic procedure according to the invention can be carried out under highly diverse conditions in regards to, for example, pH, type of buffer, temperature and concentration of the reactants.
- Various cosolvents N,N-dimethyl formamide, acetonitrile, dimethyl sulfoxide, dioxane, pyridine, methanol, ethanol, ethylene glycol, etc.
- hydrophobic acceptor substances are more easily dissolved by the use of organic cosolvents or increased temperature.
- the reactions may be carried out in two-phase systems, e.g. water- organic solvent or in two-phase systems of water-water polymer. The use of acceptors modified with organic groups facilitates recovery of the product in the organic phase.
- reaction conditions are not critical but are selected primarily on the basis of the properties of the reactants employed in the synthesis concerned, and also on the basis of practicality. For example, it may be mentioned that it is usually convenient to use a reaction temperature in the range of 25-75°C and, in the case of water-rich medium, the pH is usually in the range 4-8.
- the reaction temperature may also be varied to influence product yield and the activity and stability of the enzyme and does not restrict the scope of the invention.
- the temperatures most frequently used lie in the range 4-75°C, but lower temperatures and temperatures below 0°C can be used which can be facilitated if organic cosolvent is used.
- An advantage with high temperatures is, for example, that high substrate concentrations may be used, which reduces the water activity and thus increases the yield of product.
- Another advantage is that the activity of the enzyme increases, which means shorter reaction times at increased temperatures.
- the upper temperature limit is determined by the thermostability of the enzyme and substrate in the specific reaction medium. In some reactions the thermostability of the enzyme is increased by the use of high sugar sub ⁇ trate concentration.
- High concentration of substrate e.g. lactose (>15% w/w) can be achieved by dissolving in hot buffered water followed by cooling to the desired reaction temperature.
- the concentration of the acceptor is a parameter which can be used to influence the yield of the reactions according to the invention.
- High concentrations are usually preferable in both equilibrium and transglycosylation reactions to minimize hydrolytic side-reactions, which usually means that depending on the solubility of the acceptor, ca. 0.05 - 7 M concentration of acceptor is used.
- high concentrations of substrates are obtained by heating the reaction mixture to near the boiling point for a few minutes, allowing the solution to cool to the reaction temperature (usually 4-75°C, depending on the temperature for optimum yield and thermostability of the enzyme/substrate) followed by addition of the enzyme.
- Cosolvents can be used to increase the solubility of substrates with hydrophobic groups.
- the concentration of glycosyl donor in the reaction mixture is selected with regard to the lactosamine derivative to be synthesized and also with regard to the properties of the enzyme and therefore do not restrict the use of the invention. In some cases, addition of the donor in small p rtions may be advantageous in order to minimize the risk that the donor also acts as an acceptor (unless this is desired) . Lactose is generally used as the donor since it is a cheap substrate.
- the weight ratio of donor to acceptor is preferably _ 1 : 1 though the acceptor can be in excess.
- the enzyme may be used in ⁇ i tu or after partial or complete purification from its natural environment.
- the enzyme may be isolated before use by e.g. homogenization, precipitation and/or chromatography (e.g. based on ion-exchange, affinity, size) .
- the enzyme may be present in e.g. soluble, immobilized, cross-linked, crystalline form or be enclosed within micelles.
- the glycosidase can be used in vivo or in vi tro in a -ore or le ⁇ purified form and in different cell types (as clcned into a suitable cell type) .
- the enzyme may be produced with recombinant techniques. Then, if desired, one or.
- the amino acids in the amino acid sequence of the enzyme may be changed in order to optimize the properties of the enzyme, e.g. thermostability, catalytic efficiency and/or stability in organic solvents.
- Variants of the glycosidase produced with recombinant technology which have at least 70% homology with the peptide chain of the natural variant are, together with the naturally occurring glycosidase, also useful according to the invention.
- the synthetic reaction can be carried out with enzyme in vivo, that is under fermentation conditions with intact yeast cells and with lactose and acceptor in concentrations, for example, in the range 0.5 to 25% weight/volume.
- lactose is useful in some cases to improve the galactosylation of the acceptor and/or to prepare trisaccharides of the type mentioned above.
- This and other fermentation conditions with the necessary nutritional media/salts are easily determined by a person skilled in the art and does not limit the scope of the invention.
- glycosyl donor lactose may be used or a /--- glycoside of galactose such as an alkyl or aromatic glycoside (e.g. nitrophenyl /-f-galactoside) .
- Isolation of the product may be carried out in one or more steps involving one or more of the following procedures: extraction, chromatography (common solid supports that can be applied are e.g. Sephadex R , silica, reversed-phase silica, charcoal, charcoal-celite) , precipitation.
- chromatography common solid supports that can be applied are e.g. Sephadex R , silica, reversed-phase silica, charcoal, charcoal-celite) , precipitation.
- the reaction may be carried out at different conditions and preferably under conditions most suitable for the particular reaction. Such conditions are chosen by the person skilled in the art and do not limit the scope of the invention. Conventional pH (e.g. 4-8 obtained by e.g. acetate or phosphate buffer) and at low temperature, room temperature or at increased temperatures (e.g. in the range 0-50°C) may be use if a crude, partially isolated, or isolated enzyme preparation is employed.
- the reaction can be carried out in the presence of inert organic cosolvents in order to increase the solubility of the acceptor (e.g.
- hydrophobic acceptor or to avoid hydrolysis reactions.
- organic cosolvents e.g. acetone, acetonitrile, tetrahydrofurane
- buffered water e.g. 0°C
- concentration of substrates are then usually in the range of 30 mM-7 M.
- the enzyme may be used in soluble form or may be immobilized by e.g. adsorption, encapsulation, chelation, _
- a solid support such as a polymeric substance, or a derivative thereof which is insoluble in protic or aprotic solvents (Methods in Enzymology, vol. 135, Academic Press) .
- the form selected is not critical to the invention. If the enzyme is used in soluble form, it may if desired first have been chemically modified in a suitable manner in order to e.g. increase the thermostability or the stability in organic cosolvents.
- Enzyme immobilized to an insoluble polymer comprising, for example, agarose, cellulose, hydroxyethyl acrylate, glass, silica, polyacrylic amide, polyacrlyate-based plastics, etc., is readily separated from the product mixture, and the enzyme may thus be reused.
- immobilization examples include adsorption or covalent binding of the enzyme to a suitable solid phase such as glass, celite, silica, polysaccharides (e.g. cellulose, agarose) , or plastics (e.g. polystyrene), activated with a suitable reactive group for covalent binding of the enzyme as is known in the art (see e.g. Methods in Enzymology, volumes 44, 104 and 135) .
- the reaction conditions are chosen by the person skilled in the art and do not limit the scope of the invention. Preferable conditions are normally pH 4-7, 20-35°C in buffered water containing nutrients for the yeast cells as exemplified in the non-limiting examples below.
- Microorganisms which produce enzymes with the same structure or of a similar structure (e.g., containing similar three dimensional tertiary structure and active site structure) as the one from Bullera singularis can also be used.
- glucose i ⁇ omerase e.g. glucose i ⁇ omerase
- the product may be removed by the use of another specific enzyme, transferase, sulfatase which specifically converts the product to another desired product, thereby minimizing secondary hydrolysis of product and/or avoiding the need for isolation of the lactosamine product prior to its use in further synthesis.
- the products can be used for further enzymatic synthesis with glycosidases or glycosyltransferases .
- ⁇ -sialyltransferase can be used to catalyze the formation of sialylated Gal-GlcNAc derivatives and ⁇ -fucosyl transferase can be used to form oligosaccharide derivatives of the type Gal- (Fuc)GlcNAc-R, which then can eventually be sulphated, sialylated and/or be used for further chemical synthesis, etc.
- the products obtained with the method according to the invention may be used directly for biological applications or may be used for further synthesis to obtain various lactosamine group containing products employing enzymatic and/or chemical methods (see e.g. Example 7 below) of interest for e.g. various clinical, diagnostic, downstream processing or for food supplement purposes.
- enzymatic and/or chemical methods see e.g. Example 7 below.
- the product obtained according to the invention may also be converted by enzymatic methods using e.g. lipases, sulfatases, glycosyltransferases and oxidases . In this way hydroxyl groups of the galactosyl or glucosaminyl moiety may be selectively modified with e.g.
- acyl groups, sulphate groups, saccharide groups and other organic groups respectively thus further extending the utility of the method of the invention for preparation of different derivatives and higher saccharides containing the lactosamine group.
- Specific examples are the selection of a suitable lactosamine derivative prepared by the method according to the invention for reaction with e.g. a sialyltransferase or sulfatase to obtain e.g. an ( ⁇ 2- 3) sialylated lactosamine derivative or a 3' -O-sulphated derivative containing the lactosamine group, respectively.
- a sialyltransferase or sulfatase to obtain e.g. an ( ⁇ 2- 3) sialylated lactosamine derivative or a 3' -O-sulphated derivative containing the lactosamine group, respectively.
- the aglycon of the lactosamine containing product obtained according to the invention may not only be used in glycosylation reactions (for formation of other glycosides or for synthesis of oligosaccharides containing the lactosamine sequence) but may also be used for covalent binding to another
- nitrophenyl glycosides are for example useful after reduction to a inophenyl glycoside for covalent binding to various proteins or solid supports, which then may be used in diagnostic
- GalSl-4GlcNPht/3SEt The synthesis of GalSl-4GlcNPht/3SEt can be carried out as follows:
- Isolation of the product is carried out for example by extraction of the water-phase with a suitable solvent, e.g. ethyl acetate, which removes unreacted acceptor and the water-phase can then be extracted with a more polar solvent such as n-butanol.
- a suitable solvent e.g. ethyl acetate
- Precipitation of product from the medium such as water can be used for further purification.
- Examples of other separation methods which can be used in combination with extraction is column chromatography, using typical materials such as silica, active carbon or Sephadex ® as the solid phase, and precipitation or crystallization. Any suitable separation method known in the art can be used.
- An important advantage with the enzymatic method according to the invention is that the acceptor is not destroyed (especially when mild reaction conditions and isolated enzyme are used) , as might happen with unmodified acceptors or when chemical methods are used for synthesis.
- the non-reacted acceptor can therefore usually be recovered by e.g. the straightforward extraction procedure above.
- Compound I was prepared in a fermentation reaction or with a partially purified /?-galactosidase preparation (obtained after disintegration of yeast cells under high pressure (600 bar) ) and centrifugation of the solid material which was then used for synthesis) .
- the initial concentration of lactose (glycosyl donor) and GlcNPht/3-SEt (acceptor; compound II) were 5 and 1.2% (w/V) , respectively in yeast medium (as described above) .
- Yeast cells (Bullera 5 singularis) were added (OD600 was ca 1 after addition of the yeast cells) and the fermentation was carried out at 27°C with moderate shaking (150 rp ) at pH 5.5 for five days.
- the partially purified galactosidase preparation was used as catalyst for the reaction.
- the glycosyl donor instead of lactose as 10 the glycosyl donor, the / S-linked nitrophenyl glycoside of galactose (e.g. Gal/8-OPhN0 2 -o or Gal3-OPhN0 2 -p) can be used as glycosyl donor.
- Disaccharide part of product 103.93 (C'-l), 80.32 25 (C-1) , 70.21 (C-3) , 79.61 (C-4) , 55.65 (C-2) ;
- Compound III was prepared as in Example 1 in a fermentation reaction or with a crude /3-galactosidase preparation (obtained after disintegration of yeast cells in sodium acetate, 50 mM, pH 5, under high pressure at 600 bars) . Centrifugation gave a solid material which was used for synthesis.
- the initial concentrations of lactose (glycosyl donor) and GlcNPht / S-SEt (acceptor; compound IV) were 7 and 2.5% (w/V) , respectively, in 40 ml of 50 mM sodium acetate, pH 6.0.
- reaction was followed by TLC and by measurement of liberated nitrophenol at 405 nm (for nitrophenyl substrates) .
- isolation of product was achieved by extraction of IV with ethyl acetate, followed by chromatography and freeze-drying. In this way, product I was obtained and non-reacted acceptor was recovered and could be reused.
- Compound V was prepared as in Example 1 in a fermentation reaction or with a crude /3-galactosidase preparation (obtained after disintegration of the yeast cells suspended in sodium acetate, 50 mM, pH 5, under high pressure (600 bar) ) and centrifugation gave a solid material wh ⁇ -h was used for synthesis) .
- glycosyl donor (acceptor; compound VI) were 7 and 3% (w/V) , respectively, in 75 ml of 50 mM sodium acetate, pH 6.0. Crude /3-galactosidase preparation were added (ca 6 g) and the reaction was carried out at 30°C with gentle agitation at pH 6.0 for two days. Instead of lactose as the glycosyl donor, the ?-linked nitrophenyl glycoside of galacto ⁇ e, Gai/3-0PhN0 2 -o, was used as glycosyl donor.
- reaction was followed by TLC and by measurement of liberated nitrophenol at 405 nm (for nitrophenyl substrates) .
- isolation of product was achieved by chromatography (Sephadex and C18-silica) .
- Phthalimido group 124.04, 124.27, 133.05 (2C) , 135.50 (2C) , 169.76 (2C; OO) .
- Compound VII was prepared as in Example 1 in a fermentation reaction or with a crude /3-galactosidase preparation (obtained after disintegration of yeast cells in sodium acetate, 50 mM, pH 5, under high pressure (600 bar) and centrifugation gave a solid material which was then used for synthesis) .
- the initial concentrations of lactose (glycosyl donor) and GlcN 3 /3-OMe (acceptor; compound VIII) were 7 and 3% (w/V), respectively, in 75 ml of 50 mM sodium acetate, pH 6.0.
- Compound IX was prepared as in Example 1 in a fermentation reaction or with a crude /3-galactosidase preparation (obtained after disintegration of yeast cells in sodium acetate, 50 mM, pH 5, under high pressure (600 bar) and centrifugation gave a solid material which was then used for synthesis) .
- the initial concentrations of lactose (glycosyl donor) and GlcNAc/3-SEt (acceptor; compound X) were 7 and 5% (w/V) , respectively, in 75 ml of 50 mM sodium acetate, pH 6.0.
- this compound was prepared from lactose (7% w/w) and with p-nitrophenyl /3-D-N-acetyl-glucosaminide (0.6% w/w) as acceptor employing a crude /3-galactosidase obtained as described above at 30°C for two days.
- the compound was isolated by extraction with ethyl acetate followed by column chromatography (Sephadex G10) of the water phase.
- the product was characterized by NMR as described above. In all the above reactions, the disaccharide glycoside
- Gal/3l-4Gal/3-OPhN0 2 -o was obtained as an additional product when Gal/3-OPhN0 2 -o was used as donor.
- the acceptor substance in Examples 1-3 were prepared by standard chemical techniques known to the person skilled in the art from 2-amino-2-deoxy-D-glucosamine (GlcNH 2 ) via the peracetylated phthalimido derivative (peracetylated GlcNPht) .
- the azido acceptor substrate in Example 4 was prepared from glucose via the glucal followed by azidonitration according to standard chemical techniques known to the person skilled in the art.
- the acceptor substrates in Examples 5 and 6 were obtained via peracetylated GlcNAc by standard chemical techniques known to the person skilled in the art.
- Peracylation or other modification of compound I, III or V with standard chemical techniques gives after isolation a protected compound with a free 3-OH group in the glucosamine part.
- Compound I, III or V can first be partially modified in the hydroxyl groups via e.g. peracetylation (pyridine + acetic anhydride) . This gives after separation from other products the peracetylated compound I, III or V with a free 3-hydroxyl group and a -SEt, -OMe or OAc group, respectively, in R 1 . The resulting compound can then be reacted with a fucopyranosyl compound (e.g. peracetlyated L- fucopyranose) to give a Lewis-x derivative.
- a fucopyranosyl compound e.g. peracetlyated L- fucopyranose
- Gal/3l-4GlcNPht/?-SEt or preferably the peracetylated Compound I (IB)
- R 1 is an organic compound including a mono-, di- or higher oligosaccharide.
- the N-phthalimido group may be removed by standard techniques known in the art (e.g.
- hydrazine and the NH 2 group formed may be used for conversion to, for example, Gal / 3l-4GlcNC(0)R where R is methyl, ethyl or other organic group (see definition of NR' ' above) , or Gal/3l- 4GlcNR where R is an inorganic group (e.g. sulfate) or a compound containing an organic group (aliphatic and/or aromatic) .
- Gal / 3l-4GlcNC(0)R where R is methyl, ethyl or other organic group (see definition of NR' ' above)
- Gal/3l- 4GlcNR where R is an inorganic group (e.g. sulfate) or a compound containing an organic group (aliphatic and/or aromatic) .
- Compound I can be e.g. peracetylated (pyridine + acetic anhydride) to form a compound (IB) of the type below:
- Compound IB can be reacted with e.g. peracylated L- fucoDvranose to form Comr-our-d IC:
- Another modified form of IB, L-fuc or another sugar than fucose might be selected to give other compounds or higher yields.
- acetyl groups and phthalimido group of Compound IC can be removed by standard techniques and the NH 2 group acetylated to form Compound ID (Gal/Sl-4 (Fuc ⁇ l-3)GlcNAc/3SEt; thioethyl glycoside of Lewis-x) ; SEt can also be removed to form Compound IE (Gal / Sl-4 (Fuc ⁇ l-3)GlcNAc; Lewis-x) .
- the phthalimido group of Compound IC can be removed and the NH 2 group coupled to R-X and/or the -SEt group is used for coupling to sugar or hydroxyl group containing compound R ⁇ H to form Compound IF (Gal/Sl-4 (Fucc ⁇ l-3)GlcNR-R 1 ; a derivative of Lewis-x) where R is an inorganic or organic group and R 1 is a sugar, -OH, or organic group including amino acids or peptides.
- Example 8-Chemoenzymatic modification to obtain lactosamine containing product
- glycosyltransferases (belonging to EC group 2.4) such as Gal/3l-3/4GlcNAc_2-3sialyltransferase and Gal/31- 3/4GlcNAcc_3/4fucosyltransferase can transfer sialyl groups and fucosyl groups, respectively, to different types of lactosamine derivatives modified in the 2-N-position.
- Sialyl abbreviated as NeuAc
- Fucosyl abbreviated as Fuc
- Fuc is used herein as an abbreviation for structures of L-fucopyranose and analogs of L-fucopyranose which are transferred by fucosyltransferase.
- a suitable lactosamine derivative prepared with Bullera singularis or glycosidase according to the invention may be selected (or as obtained after chemical or enzymatic conversion of a hydroxyl group, R' ' and/or R' ' ' group of the enzymatically produced lactosamine derivative, e.g. by the use of lipase for partial acylation of e.g.
- glucosamine part by the person skilled in the art to use as an acceptor with c-2- 3sialyltransferase as catalyst and a suitable CMP-NeuAc as glycosyl donor to obtain the corresponding ⁇ 2-3sialylated lactosamine derivative NeuAcc-2-3Gal/3l-4GlcNR' '-R' ' ' .
- a suitable lactosamine derivative prepared with Bullera singularis or glycosidase according to the invention may be selected (or as obtained after chemical or enzymatic conversion of a hydroxyl group, R' ' and/or R' ' ' group of the enzymatically produced lactosamine derivative, e.g. by the use of lipase for partial acylation of e.g.
- glucosamine part by the person skilled in the art to use as an acceptor with c-l-3fucosyltransferase as catalyst and a suitable GDP-Fuc as glycosyl donor to obtain the corresponding c_2-3sialyated lactosamine derivative Gal/3l-4 (Fucc.1-3)GlcNR' ' -R' ' ' .
- a combination of the two glycosyltransferase reactions with the lactosamine derivative as the first acceptor may be selected by the person skilled in the art and used to obtain a derivative of NeuAco.2-3Gal/3l-4 (Fuc ⁇ l-3)GlcNR' ' -R' '' .
- the above derivatives can then be converted to other derivatives (e.g. by chemical modification of R' ' and/or R' ' ' groups as described above, or by further enzymatic reactions) .
- the above derivatives may be used in the various types of applications described above as appropriate. Examples are in clinical, diagnostic, downstream processing applications.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU96115931A RU2135585C1 (en) | 1994-01-06 | 1995-01-09 | Method of preparing lactosamine derivatives, lactosamine derivative prepared by this method, method of preparing levis-x compounds and their derivatives utilizing lactosamine derivatives |
EP95905840A EP0733119A1 (en) | 1994-01-06 | 1995-01-09 | Method of producing derivatives of lactosamine |
AU14298/95A AU1429895A (en) | 1994-01-06 | 1995-01-09 | Method of producing derivatives of lactosamine |
JP7518435A JPH09510694A (en) | 1994-01-06 | 1995-01-09 | Method for producing lactose amine derivative |
US08/666,542 US6653109B1 (en) | 1994-01-06 | 1995-01-09 | Method of producing derivatives of lactosamine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9400034-6 | 1994-01-06 | ||
SE9400034A SE9400034D0 (en) | 1994-01-06 | 1994-01-06 | Lactose Amine Derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995018864A1 true WO1995018864A1 (en) | 1995-07-13 |
Family
ID=20392515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1995/000010 WO1995018864A1 (en) | 1994-01-06 | 1995-01-09 | Method of producing derivatives of lactosamine |
Country Status (8)
Country | Link |
---|---|
US (2) | US6653109B1 (en) |
EP (1) | EP0733119A1 (en) |
JP (1) | JPH09510694A (en) |
CN (1) | CN1117872C (en) |
AU (1) | AU1429895A (en) |
RU (1) | RU2135585C1 (en) |
SE (1) | SE9400034D0 (en) |
WO (1) | WO1995018864A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716812A (en) * | 1995-12-12 | 1998-02-10 | The University Of British Columbia | Methods and compositions for synthesis of oligosaccharides, and the products formed thereby |
US6284494B1 (en) | 1995-12-12 | 2001-09-04 | The University Of British Columbia | Methods and compositions for synthesis of oligosaccharides using mutant glycosidase enzymes |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9301270D0 (en) * | 1993-04-19 | 1993-04-17 | BIOSENSOR | |
SE9400034D0 (en) * | 1994-01-06 | 1994-01-06 | Glycorex Ab | Lactose Amine Derivatives |
US7014049B2 (en) * | 1996-12-23 | 2006-03-21 | Glycorex Transplantation Ab | Device for bio-affinity material |
CN1094153C (en) * | 1998-10-30 | 2002-11-13 | 盐水港精糖株式会社 | Process of preparation for galactosyl sucrose |
CN102002076B (en) * | 2010-11-15 | 2013-01-16 | 浙江工业大学 | 2-deoxy-2-aryloxyacetyl amino-D-glucose compound as well as preparation and application thereof |
US11192913B2 (en) * | 2020-01-09 | 2021-12-07 | The United States of America, as represented The Secretary of Agriculture | C-glycoside amine derivatives and methods of making |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003168A1 (en) * | 1991-08-06 | 1993-02-18 | Kurt Nilsson | Enzymatic method for synthesis of carbohydrates |
WO1994029477A1 (en) * | 1993-05-14 | 1994-12-22 | Procur Ab | Method for the synthesis of amino-deoxy-disaccharides and amino-deoxy-oligosaccharides |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415665A (en) | 1980-12-12 | 1983-11-15 | Pharmacia Fine Chemicals Ab | Method of covalently binding biologically active organic substances to polymeric substances |
SE451849B (en) | 1985-12-11 | 1987-11-02 | Svenska Sockerfabriks Ab | VIEW TO SYNTHETIZE GYCLOSIDIC BINDINGS AND USE OF THIS RECEIVED PRODUCTS |
SE466403B (en) | 1988-03-24 | 1992-02-10 | Kurt G I Nilsson | SAID TO SYNTHETIZE Oligosaccharides |
SE466521B (en) | 1988-10-03 | 1992-02-24 | Kurt G I Nilsson | REAGENTS OF ANALYZE CONSISTING OF AN ENZYM AND ANOTHER LIGAND, WHICH ARE COVALENTLY BONDED TO A WATER INSULATED PARTICLE WITH A DIAMETER OF LESS THAN 500 AA |
SE465516B (en) | 1989-08-18 | 1991-09-23 | Kurt G I Nilsson | MADE TO MAKE A OLIGOSACCARIDE COMPOUND WHICH GLYCOSIDAS FROM A MOLLUSK IS USED |
US6183994B1 (en) * | 1993-05-14 | 2001-02-06 | Bioflexin Ab | N-containing saccharides and method for the synthesis of N-containing saccharides from amino-deoxy-disaccharides and amino-deoxy-oligosaccharides |
SE9400034D0 (en) * | 1994-01-06 | 1994-01-06 | Glycorex Ab | Lactose Amine Derivatives |
AU2806095A (en) * | 1995-07-13 | 1997-02-10 | Kurt G.I. Nilsson | Method of producing derivatives of glc-beta 1-4glc-n-acetyl |
US6372937B1 (en) * | 1998-11-09 | 2002-04-16 | Mark Norman Bobrow | Enhanced catalyzed reporter deposition |
-
1994
- 1994-01-06 SE SE9400034A patent/SE9400034D0/en unknown
-
1995
- 1995-01-09 RU RU96115931A patent/RU2135585C1/en not_active IP Right Cessation
- 1995-01-09 WO PCT/SE1995/000010 patent/WO1995018864A1/en active Application Filing
- 1995-01-09 JP JP7518435A patent/JPH09510694A/en active Pending
- 1995-01-09 CN CN95191167A patent/CN1117872C/en not_active Expired - Fee Related
- 1995-01-09 EP EP95905840A patent/EP0733119A1/en not_active Ceased
- 1995-01-09 AU AU14298/95A patent/AU1429895A/en not_active Abandoned
- 1995-01-09 US US08/666,542 patent/US6653109B1/en not_active Expired - Fee Related
-
2003
- 2003-10-03 US US10/679,194 patent/US20040162424A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003168A1 (en) * | 1991-08-06 | 1993-02-18 | Kurt Nilsson | Enzymatic method for synthesis of carbohydrates |
WO1994029477A1 (en) * | 1993-05-14 | 1994-12-22 | Procur Ab | Method for the synthesis of amino-deoxy-disaccharides and amino-deoxy-oligosaccharides |
Non-Patent Citations (2)
Title |
---|
KATSUMI AJISAKA ET AL.: "Regioselective Transglycosylation in the Synthesis of Oligosaccharides: Comparison of Beta-Galactosidases and Sialidases of Various Origins", CARBOHYDRATE RESEARCH, vol. 259, 1994, pages 103 - 115, XP002961424 * |
KAZUO SAKAI ET AL.: "Enzymatic Syntheses of N-Acetyllactosamine and N-Acetyllolactosamine by the Use of Beta-D-Galactosidases", J. CARBOHYDRATE CHEMISTRY, vol. 11, no. 5, 1992, pages 553 - 565, XP000600026 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716812A (en) * | 1995-12-12 | 1998-02-10 | The University Of British Columbia | Methods and compositions for synthesis of oligosaccharides, and the products formed thereby |
US6284494B1 (en) | 1995-12-12 | 2001-09-04 | The University Of British Columbia | Methods and compositions for synthesis of oligosaccharides using mutant glycosidase enzymes |
US7078194B2 (en) | 1995-12-12 | 2006-07-18 | The University Of British Columbia | Methods and compositions for synthesis of oligosaccharides using mutant glycosidase enzymes |
Also Published As
Publication number | Publication date |
---|---|
CN1117872C (en) | 2003-08-13 |
AU1429895A (en) | 1995-08-01 |
SE9400034D0 (en) | 1994-01-06 |
RU2135585C1 (en) | 1999-08-27 |
EP0733119A1 (en) | 1996-09-25 |
US20040162424A1 (en) | 2004-08-19 |
JPH09510694A (en) | 1997-10-28 |
US6653109B1 (en) | 2003-11-25 |
CN1138351A (en) | 1996-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5856143A (en) | N-containing saccharides and method for the synthesis of N-containing saccharides from amino-deoxy-disaccharides and amino-deoxy-oligosaccharides | |
Nilsson | Enzymatic synthesis of oligosaccharides | |
US5532147A (en) | Enzymatic method for synthesis of carbohydrates | |
Nilsson | Synthesis with glycosidases | |
US5372937A (en) | Process for producing an oligosaccharide compound by using glycosidases from a mollusc | |
US20100121041A1 (en) | Method for production of sugar oxazoline derivative | |
US6653109B1 (en) | Method of producing derivatives of lactosamine | |
US6077695A (en) | Method of producing derivatives of Glc-β 1-4Glc-N-acetyl | |
Taubken et al. | Syntheses of β-Mannopyranosedes by Enzymatic Approaches | |
US5882902A (en) | Amino acid conjugate | |
Planas et al. | Glycosidases and glycosynthases in enzymatic synthesis of oligosaccharides: an overview | |
Wang et al. | Chemoenzymatic syntheses of tumor‐associated carbohydrate antigen Globo‐H and stage‐specific embryonic antigen 4 | |
US6183994B1 (en) | N-containing saccharides and method for the synthesis of N-containing saccharides from amino-deoxy-disaccharides and amino-deoxy-oligosaccharides | |
Nilsson et al. | Syntheses of modified carbohydrates with glycosidases: Stereo-and regiospecific syntheses of lactosamine derivatives and related compounds | |
EP0736101A1 (en) | Enzymatic method for synthesis of o-glycosylated amino acid or peptide or derivatives thereof | |
Thiem et al. | Glycoscience: synthesis of oligosaccharides and glycoconjugates | |
US5936075A (en) | Amino-deoxy-disaccharides and amino-deoxy-oligosaccharides | |
WO2000012747A1 (en) | Method for enzymatic synthesis of glycosides, disaccharides, and oligosaccharides | |
KR100260097B1 (en) | Method for producing lactosamine using beta-galactosidase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95191167.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08666542 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995905840 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995905840 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |